期刊文献+

顺式阿曲库铵闭环注射系统在腹腔镜手术中的应用 被引量:19

The use of cis-atracurium by guidance of closed-loop muscle relaxant injection system in the laparoscopic surgery
下载PDF
导出
摘要 目的探讨顺式阿曲库铵闭环注射在腹腔镜手术中的肌松效果。方法选择腹腔镜手术患者20例,随机均分成闭环注射组(G组)和对照组(C组)。C组持续输注顺式阿曲库铵1.5~2μg·kg-1·min-1直至手术结束前30min;G组输注顺式阿曲库铵0.8μg·kg-1·min-1,设定肌松深度反馈值T1=15%,近手术结束时由研究实施者根据术中肌松监测指标决定停药时机。记录麻醉时间、顺式阿曲库铵的总用量、恢复指数、TOFr75及TOFr90。结果 G组顺式阿曲库铵总用量均明显少于C组(P<0.05),恢复指数、TOFr75及TOFr90明显缩短于C组(P<0.05)。结论与持续输注方式相比,闭环肌松药注射方式肌松药用量更少,恢复指数、TOFr75和TOFr90明显缩短,实现个性化和合理化用药。 Objective To explore the effect of closed-loop muscle relaxant injection system on the dosage of cis-atracuriurru Methods Twenty patients, scheduled to accept laparoscopic surgery, were randomly divided into two groups: continuous infusion group(group C) and guidance group (group G). Keeping the ram velocity of cis-atraeurium at 1.5-2ug.kg-1 .min 1 in group C until 30 minutes before the end of surgery. Keeping the ram velocity of cis-atracurium at 0. 8ug.kg-1 .min-1 in group G, and setting the feedback value of muscle relaxation depth (T1) at 15%. Reserchers withdrew the relaxant according to the monitoring information nearby the end of surgery. The duration of anesthesia, the total amount of cis-atracurium, recovery index (RI), TOFr75, and TOFr90 were recorded. Results The total amount of cis-atracurium in group G was lower than group C(P(0.05). Compared to group C,RI, recovery time, TOFr75 and TOFr90 in group G significantly shortened(P〈0.05). Conclusion Compared to the continuous injection mode, the total consumption of relaxant in the closed-loop injection system was less; in addition, the RI, TOFr75 and TOFr90 were shortened. It can personalize and rationalize the drug usage.
出处 《临床麻醉学杂志》 CAS CSCD 北大核心 2012年第12期1152-1154,共3页 Journal of Clinical Anesthesiology
基金 北京市科技计划课题(Z121107001012160)
关键词 肌松监测 闭环肌松注射系统 顺式阿曲库铵 腹腔镜手术 Neuro musealar monitoring Closed-loop muscle relaxant injection system Cis-atracurium Laparoscopic surgery
  • 相关文献

参考文献8

  • 1Murphy GS,Brull SJ. Residual neuromuscular block:lessons unlearned.Part Ⅰ:definitions,incidence,and adversephysiologic effects of residual neuromuscular block[J].Anesthesia and Analgesia,2010,(01):120-128.
  • 2Brull SJ,Murphy GS. Residual neuromuscular block:lessons unlearned.Part Ⅱ:methods to reduce the risk of residual weakness[J].Anesthesia and Analgesia,2010,(01):129-140.
  • 3谷媛媛,彭云水,宋子贤,贾慧群.CHRNA1基因多态性对罗库溴铵肌松效应的影响[J].中华麻醉学杂志,2010,30(8):910-912. 被引量:7
  • 4Saitoh Y,Kaneda K,Hattori H. Monitoring of neuromuscular block after administration of vecuronium in patients with diabetes mellitus[J].British Journal of Anaesthesia,2003,(04):480-486.
  • 5Taylor MR. Pharmacogenetics of the human beta-adrenergic receptors[J].Pharmacogenomics,2007,(01):29-37.
  • 6Kopman AF,Zank LM,Ng J. Antagonism of cisatracurium and rocuronium block at a tactile train-of-fourcount of 2:should quantitative assessment of neuromuscular function be mandatory[J].Anest h Analg,2004,(01):102-161.
  • 7Maybauer DM,Geldner G,Blobner M. Incidence and duration of residual paralysis at the end of surgery after multiple administrations of cisatracurium and rocuroniur[J].Anaesthesia,2007,(01):12-17.
  • 8Plaud B,Debaene B,Donati F. Residual paralysis after emergence from anesthesia[J].Anesthesiology,2010,(04):1013-1022.doi:10.1097/ALN.0b013e3181cded07.

二级参考文献6

  • 1Zheng Y,Wheatley LM,Liu T,et al.Acetylcholine receptor alpha subunit mRNA expression in human thymus:augmented expression in myasthenia gravis and upregulation by interferon-gamma.Clin Immunol,1999,91(2):170-177.
  • 2Wilisch A,Gutsche S,Hoffacker V,et al.Association of acetylcholine receptor alpha-subunit gene expression in mixed thymoma with myasthenia gravis.Neurology,1999,52(7):1460-1466.
  • 3Wang HL,Auerbach A,Bren N,et al.Mutation in the M1 domain of the acetylcholine receptor alpha subunit decreases the rate of agonist dissociation.J Gen Physiol,1997,109(6):757-766.
  • 4Naguib M,Samarkandi AH,Bakhamees HS,et al.Comparative potency of steroidal neuromuscular blocking drugs and isobolographic analysis of the interaction between rocuronium and other aminosteroids.Br J Anaesth,1995,75(1):37-42.
  • 5Barnes B,Lubyova B,Pitha PM.On the role of IRF in host defense.J Interferon Cytokine Res,2002,22(1):59-71.
  • 6Lohoff M,Mak TW.Roles of interferon-regulatory factors in T-helpercell differentiation.Nat Rev Immunol,2005,5(2):125-135.

共引文献6

同被引文献157

引证文献19

二级引证文献82

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部